Literature DB >> 9325182

Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation.

M Barton1, S Shaw, L V d'Uscio, P Moreau, T F Lüscher.   

Abstract

Angiotensin II (Ang II)-stimulated expression of endothelin-1 (ET-1) mRNA is blocked by ETA antagonists in vitro. We studied effects of Ang II (200 ng/kg/min) and ETA antagonist LU135252 (50 mg/kg/d) in WKY rats in vivo investigating vascular and renal ET-1 protein expression, functional endothelin converting enzyme (ECE) activity, and clearance of (125I)ET-1. Infusion of Ang II for two weeks increased ET-1 protein content in aorta (4.7-fold) and femoral artery (1.6-fold) with and without endothelium and in kidneys (3-fold, p<0.05) and enhanced functional ECE activity (p<0.05). The Ang II-induced increase in tissue ET-1 content and functional ECE activity was completely prevented by LU135252 (p<0.05). Chronic treatment of control animals with LU135252 lowered basal vascular but not renal ET-1 content (p<0.05 vs. control). Clearance of 125IET-1 was unaffected by the treatments. It is concluded that Ang II increases ET-1 protein and functional ECE activity in vascular smooth muscle and kidney through ETA-receptors in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325182     DOI: 10.1006/bbrc.1997.7394

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

Review 1.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 3.  Chronic heart failure and the immune system.

Authors:  Daniela Mari; Federica Di Berardino; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 4.  The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.

Authors:  Marilyn J Cipolla; David S Liebeskind; Siu-Lung Chan
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-10       Impact factor: 6.200

Review 5.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

Authors:  M Barton; W Kiowski
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

6.  Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries.

Authors:  Matthias R Meyer; Natalie C Fredette; Matthias Barton; Eric R Prossnitz
Journal:  Life Sci       Date:  2014-03-05       Impact factor: 5.037

Review 7.  Nox1 downregulators: A new class of therapeutics.

Authors:  Matthias Barton; Matthias R Meyer; Eric R Prossnitz
Journal:  Steroids       Date:  2019-09-10       Impact factor: 2.668

8.  Functional heterogeneity of NADPH oxidase-mediated contractions to endothelin with vascular aging.

Authors:  Matthias R Meyer; Matthias Barton; Eric R Prossnitz
Journal:  Life Sci       Date:  2013-12-29       Impact factor: 5.037

9.  Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.

Authors:  G Wölkart; X Pang; H Stessel; M Kirchengast; F Brunner
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

10.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.